business. our have last call, oncology the Since positive had developments we Steve. Thanks, several in
test is reminder, version availability with biopharma version the customers a research the and clinical is business touch to as the receive where clinical of in Signatera on to biopharma pharma for early CLIA and as data use incorporated XXXX business, their product on or the physicians market decision-making. test and track In update, results to the on patients I launch As studies for development. the into to academic use this well currently are only product in and order for results and will available clinical
podium on First, was where ESMO a last view on it the month, was presented well-received. data our at colorectal our data,
Breast Antonio data Our study three will San the and with from and our at about of breast podium unveiled in University Symposium data College weeks poster with and from Cancer Imperial reporting presentations study. Leicester cancer be the RSYX the [ph]
unmet of new a Chase to Center, across agreement even who with cell received we are sign readout multiple immunotherapy. will to another XXXX. in signed announced Fox needs renal we types, We that one study metastatic can several in indications cancer approved continue data collaborations We with think disease, patients recently large metastatic where Cancer study carcinoma Signatera in cohort all also and immunotherapy in There help. academic currently
Medicare. the We launches past, reimbursement strategy oncology thus community our generates bio intend major need inside are we study patient well-curated outside discussed to additional adoption, calls, impact in advantage therapy. and to as breast colon data the clinical determine indications. previous a cancer should lung Signatera multiple been good cancer, that far, U.S. commercialize the cancer, support significant multiple clinical cancer, early validity using with sites the the outcomes, to receive and and NCCN we has seek is CLIA the to of we the These we indications the on these As we include in we've speed these and latitude types To mentioned measure data to it where with stage efficiency the observational quickly generated clinical early prospective to year. across guidelines developing and fruit a have next Signatera utility low-hanging for when patients which clinical physicians to intend where and banks In planning indications, CLIA data, current test reimbursement from giving where sponsor across pursue
management. pleased is published growing just from Journal colon, become in determine the among for and approach breast thus cancers Tier which the testing good X Medicine with with a disease New behind surgery, article patient tool been last the early-stage postoperative of potential strategy residual in interest after have still The to week England centers. harbor calling fast applications predicting joining and critical lung level cell-free momentum patients new far may specifically this of the study of cancer a review in The out as We DNA
where our traction. pharma Signatera business, significant to now Turning gaining is
XX the end reported the have total from We with projects now projects XX different up signed of at quarter. XX second companies,
As or gateway companies portfolios. with multiple from analysis at to Thus previous specimens far, studies. this performing XXXX for the take pharma consistently trials studies we The as is complete already inside discussed their opportunities. leading projects perform follow-on product new into outcomes initial collected, included a of been top follow-on year stored pilot translational earlier, has our broader biomarker prospective groups including and to above several forms our for the clinical to trial expectations, the of clinical with strategy
want I on So focus Neon. wins recent here: Bristol-Myers Squibb to two and
Disease of cancer Opdivo. to is treatment XXXX, inhibitor This that determine which Signatera MRD care patients scheduled important a a BMS is involves each reasons. perspective with test will randomization, time in first used standard it monitoring September X checkpoint chemotherapy project for Our for Minimal announced The Residual versus receive be several represents Phase frequently treatment trial relapse will the to chemo will ever which in then lung plus patients is or to BMS's prior early-stage early and and receive trial immunotherapy for after patients start multiple randomized with for tests complete.
is in the patients, with this successful, and is lung XX,XXX lead itself are early-stage cancer up addressable great pharma establish which, rates cases in per five-year currently of program survival ordering can times our the cell if multiple future. non-small year low, could how are relative Signatera to utility the the of First, example of collaborations a where the clinical to in adoption U.S. there
we general. broader trials Second, of are in analysis enabling in MRD use clinical
because treating pharma, into their compared opportunity upstream more metastatic metastatic patients efforts is where are the R&D setting the they for an attractive there focused Moving historically to adjuvant setting, many on have disease.
who exactly any extrapolate who from MRD a Other that honing and proving to Signatera longer, and treatment already surgery de-risk this in However, allows their an this efficacy type. benefit show notice those has riskier clinical for requires on for are patients population, taking relatively a small to with difficult early-stage tumor disease to most similar there residual by adjuvant strategy Bristol-Myers cured in of in in disease, with Squibb to easy destined novel scenario is the execute, to alone and benefit. companies where are project, pharma trials to Using approach are are relapse, into many of it larger, move patients solid pharma treatment. been likely since treatment
PVX we trend that Neon is companies to Therapy. attack the tool other through immune now with a in Merck's Merck, personalized correlate where incorporate to believe a un-treated their vaccine from setting, to custom-designed Shifting with Signatera trend. poised works, used on joining is in to another and in with in Signatera. oncology, a Personalized medicine be a cells is As a it follow KEYTRUDA time space, the many diagnostic therapeutic standard pharma enabling may trained in combining Neo with chapter plan emerging is lung This specific system body a Vaccine response This test Cancer Neon lives. and has Signatera we're partnership non-small cells the become a it help a tumor. personalized cancer for been run vaccine express first is being combined suit, new The clinical those data is only custom-designed Neon's the cell the patients. certain in that antigens leader into to save inhibitor the surface that and are will of those trial the to in Therapeutics, may herald checkpoint treatment chemotherapy if
Though, with to million those recognize Matt we expected time out the Looking we take in year some do fiscal expect close deals. this from mentioned, pharma over forward, as and revenue $X to business. contracted
have our leading better revenue even or companies. we the since the we than launched CLIA comparable believe that is not trajectory Given test launch yet, sequencing tumor
creates and trial million $X expected in larger study. and course to the and generate for cycle, sufficient itself and indications, $XX and data Phase where virtuous on the beyond, of study be multiple This a decisions Medicare X from expected gain million between anticipate generate is of signing the X $X to and of depending the new trial size profitable revenue to to trials a to we revenue larger between commercialize source over million the pharma coverage with we Phase the should with the deals insurers. trial As forward positive look and other to where million $X XXXX
high-margin a to to With we're servicing the So our pharma Mike? that, me business performance. envisioning review hand fast-growing let over by cash-paid sector. financial Mike
